Nitroglycerin as a Treatment Modality for Recurrent Isolated Paracentral Acute Middle Maculopathy: A Case Report

Jason K. Sendek 1, Anita Goyal 2, Robert G. Josephberg 2

1. Ophthalmology, Briarcliff High School, Briarcliff Manor, USA 2. Ophthalmology, New York Medical College, Valhalla, USA

Corresponding author: Robert G. Josephberg, rj2526@aol.com

Abstract

Paracentral acute middle maculopathy (PAMM) is a condition characterized by ischemia affecting the deep capillary plexus layer of the macula, often resulting in a paracentral visual scotoma. PAMM has been reported in association with retinal vascular diseases or as an isolated phenomenon in young and healthy individuals. There is currently no treatment for PAMM. We report a case in which sublingual nitroglycerin reversed developing visual scotomas, or blind spots, in a patient with known recurrent episodes of PAMM.

This case describes a male patient with previously documented evidence of PAMM in both eyes following episodes of extreme physical activity or dehydration. These episodes would often last days without ultimate resolution. After one such occurrence in his right eye, the patient was treated with a sublingual nitroglycerin tablet immediately after the development of new visual scotomas. The patient’s visual symptoms improved within minutes of administering sublingual nitroglycerin, and completely resolved within hours.

Categories: Ophthalmology, Therapeutics, Oral Medicine
Keywords: nitroglycerin, retina, lesion, scotoma, pamm

Introduction

Paracentral acute middle maculopathy (PAMM) is a condition characterized by acute onset of paracentral visual scotoma and is thought to be caused by ischemia of the middle retinal layers [1]. While there is no incidence rate in the United States, one study reported a 3.8% incidence rate (15/395) of patients who fit eligible criteria [2]. PAMM was first characterized in 2013, as a distinct hyperreflective band-like spectral-domain optical coherence tomography (OCT) lesion at the level of the inner nuclear layer. The lesion is typically seen with near-infrared reflectance imaging in the parafoveal region. PAMM lesions are thought to be caused by localized retinal capillary ischemia and can be the cause of persistent scotomas. These lesions often result in thinning and atrophy of the affected inner nuclear layer, accounting for the permanent visual defects that patients with PAMM typically experience [1]. PAMM may occur in conjunction with other retinal vascular disorders such as branch retinal vein occlusion, central retinal artery occlusion, or occur as an isolated entity in healthy, young individuals [3].

PAMM lesions occur in the parafoveal region of the macula, which is a region particularly susceptible to ischemic insults [4]. The oxygen demand of the macula is higher than any other region of the retina. Oxygen diffusion from the choroid to the retina is limited by retinal thickness, which is greatest parafoveally. The middle retinal layers of the parafoveal macula have been described as a watershed-like region, which has a high perfusion demand whose supply is limited by its structure, placing it at the greatest risk for an ischemic insult [5].

When PAMM is discovered in an apparently healthy individual with no risk factors, the individual should undergo a systemic work-up to rule out any underlying vascular disease [6]. Medications, such as amphetamines, caffeine, vasopressors, and oral contraceptives, have been reported in association with PAMM. In addition, migraines, severe hypovolemia, orbital compression injury, and viral illness have been linked to PAMM [7]. The clinical diagnosis of PAMM is based on a patient’s history of an acute onset of a negative scotoma with no other ocular symptoms. PAMM can develop in younger individuals with no ocular history, or without preceding visual symptoms. PAMM lesions may appear as subtle grey parafoveal lesions within the retina on fundoscopy. Fundusscopic examination may not reveal the reason for the subtle scotomas as described by the patient; however, spectral-domain OCT imaging allows for the capturing of the findings on the detailed images of the retina [8].

Currently, there is no treatment for PAMM, but treatment for the underlying cause is often necessary. Symptomatic scotomas may fade but often are persistent [9]. With no definitive cure, new treatments must...
be tested to assess the efficacy to reduce the effects of ischemia. There are several reports that discuss the use of sublingual nitroglycerin as an effective therapy for episodes of acute loss of vision due to vascular occlusion. We hypothesized that in our patient, nitroglycerin could potentially play a role in reversal of retinal capillary ischemia and visual symptoms.

Nitrates work on the muscle walls of the veins and arteries. When nitroglycerin enters the bloodstream, it is converted to nitric oxide, which acts on the veins and arteries. Nitric oxide is a powerful vasodilator that causes relaxation of the vascular tone [10]. This dilation affects blood flow, perfusion pressure, and flow resistance as these three systems are dependent on others. As the radius of the retinal blood vessels decrease or constrict, the perfusion pressure will decrease, slowing the flow of blood through the retina. When the radius of the retinal blood vessels dilate or increase, the opposite occurs.

In an article published in 1990 by Dr. Sharon Kuritzky, two patients are described with sudden total loss of vision from one of their eyes, treated effectively with 0.4 mg of nitroglycerin sublingually [11]. In 1983, a study was conducted by Wizemann et al., showing that nitroglycerin produced complete recanalization of experimentally produced retinal artery occlusion in rats [12]. In another study published in 1998, scientists induced branch vein occlusion in miniature pigs, and found that intravenous administration of the nitric oxide donor, sodium nitroprusside, reversed arteriolar vasoconstriction [13].

Nitroglycerin is usually a safe, widely used medication whose side effects are rapidly reversible. Previous studies have found that nitroglycerin may be efficacious in the treatment of acute retinal vascular conditions. This case report is unique in that it documents the first reported case of a proposed treatment for PAMM in a patient with recurrent episodes in both eyes of PAMM.

Case Presentation

A 47-year-old Caucasian male with a history of an aortic valve replacement, Factor V Leiden anomaly, migraines, and a competitive cycling hobby presented with new paracentral blind spots in the right eye following a fishing trip in Florida on August 28, 2014. The patient reported that the vision loss began during a fishing trip when he became dehydrated and had not resolved. He described three to four similar events that occurred previously following episodes of extreme physical activity, however, all resolving. On presentation in 2016, visual acuity was 20/20 in both eyes. No fundus abnormalities were noted. Amsler grid testing revealed two scotomas about 1 and 4 degrees superior nasal to fixation in the right eye. Spectral-domain OCT imaging also revealed several hyperreflective bands in the middle retina of the right eye (Figure 1). In Figure 2, the hyporeflective lesions seen at the border of the fovea inferior temporal and slightly further out were consistent with his subjective superior nasal scotomas on Amsler grid testing. Spectral-domain OCT findings of PAMM were corroborated with the Chief of the Retinal Service at the New York Eye and Ear Infirmary. The patient was diagnosed with findings consistent with PAMM. At that time, no treatment was given. While diagnostic measures were not taken during this patient’s first few described episodes, it was thought that the previous episodes were also consistent with PAMM, given their similar presentation on the Amsler grid testing and symptomatology.

**FIGURE 1:** Image of the OCT B scan cross section shows the hyperreflective lesions (white bright spots) in the middle retina of the right eye

OCT, optical coherence tomography
In mid-2018, the patient presented with a left-sided visual scotoma that had developed following a recent episode of febrile gastroenteritis. Treatment started with niacinamide OTC minerals, which helped initially over 30-40 minutes. After consulting with his cardiologist, nitroglycerin was prescribed but not taken. The patient was treated with 325 mg of aspirin and 200 mg of ibuprofen every 4 hours, with minimal relief. Aspirin and ibuprofen were administered because they are anti-inflammatory and blood thinners. The scotoma improved over the course of the next week but did not fully resolve. A permanent small scotoma remained.

In 2019, the patient began to experience similar symptoms after vigorous exercise. The patient was treated with 0.4 mg nitroglycerin sublingually previously prescribed by his cardiologist. Within 45 minutes, the visual scotoma improved, and within a few hours, it completely resolved. Since this occasion, the patient experienced two subsequent episodes of the development of visual scotomas, both resolving within minutes of the administration of sublingual nitroglycerin.

The patient described the lesions as permanent obstructions in the field of vision. They appear as small opaque structures, with a purple hue. The structures blend into the background without a distinct outline. The right eye lesions seen in Figure 1 appeared at about 11 o’clock in the field of the patient’s vision and did not move.

Discussion
PAMM was first characterized in 2013 as a lesion involving the middle layer (inner nuclear layer) of the
Another study sets out to answer if isosorbide mononitrate nitrate influences blood flow in the optic nerve administration, through the effects of nitric oxide, reversed arteriolar and capillary plexus ischemia causing restoration of arteriolar blood supply delivery of nitric oxide to the retinal circulation, and therefore may significantly contribute to the vein occlusion. The study suggests that nitric oxide donors may provide an efficient means for continuous branch retinal vein occlusion, it was found that preretinal intravitreous administration of the nitric oxide vasoconstriction. In a study performed on the effect of nitroprusside on arteriolar constriction after retinal Studies have shown that nitrates, or nitric oxide donors, may cause a reversal of retinal vessel pressure, and that a 5% change in retinal blood vessel caliber represents a 20% change in blood flow administration in human subjects altered retinal vessel caliber significantly; sublingual administration of Nitroglycerin is a potent vasodilator that has been studied in relation to retinal blood flow. Nitroglycerin disease, and several of his episodes resulted in permanent visual scotomas, unlike amaurosis fugax. One may hypothesize that amaurosis fugax was the cause of this patient's previous episodes of visual scotomas; however, this hypothesis was rejected, as this patient had no history or findings of carotid artery disease, and several of his episodes resulted in permanent visual scotomas, unlike amaurosis fugax.

Nitroglycerin is a potent vasodilator that has been studied in relation to retinal blood flow. Nitroglycerin administration in human subjects altered retinal vessel caliber significantly; sublingual administration of 0.64 mg nitroglycerin produced a highly significant dilatation in both retinal arteries (6%) and veins (5%). The authors report that retinal circulation supplying the parafovea is autoregulated in relation to perfusion pressure, and that a 5% change in retinal blood vessel caliber represents a 20% change in blood flow[16]. Studies have shown that nitrates, or nitric oxide donors, may cause a reversal of retinal vessel vasoconstriction. In a study performed on the effect of nitroprusside on arteriolar constriction after retinal branch retinal vein occlusion, it was found that preretinal intravitreous administration of the nitric oxide donor sodium nitroprusside reversed arteriolar vasoconstriction that occurred in parallel with the branch vein occlusion. The study suggests that nitric oxide donors may provide an efficient means for continuous delivery of nitric oxide to the retinal circulation, and therefore may significantly contribute to the restoration of arteriolar blood supply[13]. In our patient, it is hypothesized that nitroglycerin administration, through the effects of nitric oxide, reversed arteriolar and capillary plexus ischemia causing the characteristic inner nuclear layer lesions seen in PAMM.

Another study sets out to answer if isosorbide mononitrate nitrate influences blood flow in the optic nerve...
head and choroid. The 12-subject study, following nitrate intake, showed optic nerve flow increase from baseline of 19.8% [17]. The profound effects caused by nitroglycerin appears to be the result of it working more on the veins rather than their arterial counterparts [18]. This is especially interesting because it was proven that the deep capillary plexus serves as a primary site of venous outflow, which happens to be a common location for PAMM lesions to develop.

In our patient, the etiology of his recurrent paracentral visual scotomas was felt to be most consistent with PAMM. Although the patient does have a history of possible hypercoagulable state secondary to Factor V Leiden anomaly, a thromboembolic event was felt to be unlikely given normal fundus examination and fluorescein angiography. Presumably, carotid artery disease did not contribute as our patient had no preceding risk factors or history of such disease. Ocular migraine was additionally less likely given the permanent nature of one of his episodes of visual scotoma. Given that the patient had spectral-domain OCT imaging evidence of hyperreflective bands at the level of the inner nuclear layer, it is most likely that the patient’s recurrent episodes of visual scotomas are secondary to PAMM, thought to be precipitated by hypovolemia secondary to severe dehydration and/or severe physical exertion. At this point in the patient’s life, he has no other active medical problems. The prescription of nitroglycerin was consented to by the patient, and he was given the nitroglycerin prescription by his cardiologist. Nitroglycerin is approved by the FDA in the United States for cardiac conditions, and once approved can be prescribed off-label legally for any other conditions as well as with all other drugs similarly approved by the FDA. Also, there were no ethical concerns since everybody (patient and doctor) mutually agreed in writing and verbally on the decision.

Conclusions
We report a unique case report of a patient with recurrent PAMM treated with sublingual nitroglycerin after the onset of visual scotomas. This report suggests that nitroglycerin may play a role in the reversal of retinal capillary ischemia and could potentially be used in the treatment of other ischemic vascular conditions.

While this conclusion is not definitive solely from this report, we have shown that this sort of treatment has been effective on numerous other occasions as well, further supporting our conclusion. This case report’s purpose is to make other physicians aware of a possible treatment benefit. Underlying conditions matter, but none were treatable in this report. The patient’s cardiovascular history with an aortic valve replacement may have influenced the result outputs, but unlikely given the data. Hydration did not work, and most episodes were brought upon from demanding exercise, rather than dehydration. Further studies are needed to better establish the role of nitroglycerin in ischemic vascular conditions.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Rahimy E, Sarraf D: Paracentral acute middle maculopathy spectral-domain optical coherence tomography feature of deep capillary ischemia. Curr Opin Ophthalmol. 2014, 25:207–12. 10.1097/ICJ.0000000000000045
2. Nakashima H, Iwama Y, Tanioka K, Emi K: Paracentral acute middle maculopathy following vitrectomy for proliferative diabetic retinopathy: incidence, risk factors, and clinical characteristics. Ophthalimology. 2018, 125:1929–36. 10.1016/j.ophtha.2018.07.006
3. Christenbury JG, Klufas MA, Sauer TC, Sarraf D: OCT angiography of paracentral acute middle maculopathy associated with central retinal artery occlusion and deep capillary ischemia. Ophthalmic Surg Lasers Imaging Retina. 2015, 46:579-81. 10.3928/23258160-20150521-11
4. Sarraf D, Rahimy E, Fawzi AA, et al.: Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol. 2015, 131:1275-87. 10.1001/jamaophthalmol.2015.4056
5. Yu S, Wang F, Pang CE, Yannuzzi LA, Freund KB: Multimodal imaging findings in retinal deep capillary ischemia. Retina. 2014, 34:636-46. 10.1097/IAE.0000000000000048
6. Yu S, Pang CE, Gong Y, et al.: The spectrum of superficial and deep capillary ischemia in retinal artery occlusion. Am J Ophthalmol. 2015, 159:53-65.e1-2. 10.1016/j.ajo.2014.09.027
7. Chen X, Rahimy E, Sergott RC, et al.: Spectrum of retinal vascular diseases associated with paracentral acute middle maculopathy. Am J Ophthalmol. 2015, 160:26-34.e1. 10.1016/j.ajo.2015.04.004
8. Provis JM: Development of the primate retinal vasculature. Prog Retin Eye Res. 2001, 20:799-821. 10.1016/s1350-9462(01)00012-x
9. Rahimy E, Kuehlewein L, Sadda SR, Sarraf D: Paracentral acute middle maculopathy: what we knew then and what we know now. Retina. 2015, 35:1921-30. 10.1097/IAE.0000000000000785
10. Kuritzky S: Nitroglycerin to treat acute loss of vision. N Engl J Med. 1990, 323:1428. 10.1056/NEJM199011153232019
11. Wizemann A, Maier TH, Wizemann V: [Efficacy of different therapeutic principles in experimental retinal vessel occlusions]. Fortschr Ophthalmol. 1983, 80:176-8.

12. Donati G, Pournaras CJ, Tsacopoulos M: Effect of nitroprusside on arteriolar constriction after retinal branch vein occlusion. Invest Ophthalmol Vis Sci. 1998, 39:1910-7.

13. Sinclair AM, Hughes AD, Sever PS: Effect of nifedipine and glyceryl trinitrate on retinal blood flow in normal subjects. J Hum Hypertens. 1995, 7:399-401.

14. Steigerwalt RD Jr, Pascarella A, De Angelis M, Grimaldi G, Nebbioso M: Three episodes of non-arteritic posterior ischemic optic neuropathy in the same patient treated with intravenous prostaglandin E1. Drug Discov Ther. 2016, 10:177-80. 10.5582/ddt.2016.01056

15. Al-Moujahed A, Hien DL, Akhavanrezayat A, et al.: Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiacis-Behçet’s disease. Am J Ophthalmol Case Rep. 2021, 21:101027. 10.1016/j.ajoc.2021.101027

16. Frayser R, Hickam JB: Effect of vasodilator drugs on the retinal blood flow in man. Arch Ophthalmol. 1965, 73:640-2. 10.1001/archoph.1965.00970030642008

17. Grumwald JE, Iannaccone A, DuPont J: Effect of isosorbide mononitrate on the human optic nerve and choroidal circulations. Br J Ophthalmol. 1999, 83:162-7. 10.1136/bjo.83.2.162

18. Kim KH, Kerndt CC, Adnan G, Schaller DJ: Nitroglycerin. StatPearls [Internet]. StatPearls Publishing, Treasure Island, Fl; 2021.